1 week Ago By Defense World Staff
Vanguard Group Inc. increased its stake in shares of Kura Oncology, Inc. (NASDAQ:KURA – Free Report) by 14.
6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 4,818,898 shares of the company’s stock after purchasing an additional 615,211 shares during the period. Vanguard Group Inc.
owned 6.20% of Kura Oncology worth $41,973,000 as of its most recent filing with the Securities & Exchange Commission. Other hedge funds have also recently modified their holdings of the company.
Wealthfront Advisers LLC purchased a new stake in Kura Oncology during the 4th quarter worth approximately $1,289,000. Barclays PLC increased its position in shares of Kura Oncology by 104.5% during the third quarter.
Barclays PLC now owns 165,484 shares of the company’s stock worth $3,234,000 after purchasing an additional 84,563 shares in the last quarter. Jennison Associates LLC acquired a new position in Kura Oncology in the 4th quarter valued at $623,000. SG Americas Securities LLC acquired a new position in Kura Oncology in the 4th quarter valued at $436,000.
Finally, Moody Aldrich Partners LLC lifted its holdings in Kura Oncology by 42.3% in the 4th quarter. Moody Aldrich Partners LLC now owns 143,587 shares of the company’s stock valued at $1,251,000 after purchasing an additional 42,712 shares in the last quarter.
Insiders Place Their BetsIn other news, insider Mollie Leoni sold 4,963 shares of the company’s stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.
81. Following the transaction, the insider now directly owns 88,253 shares in the company, valued at approximately $694,551.11.
This represents a 5.32 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Also, SVP Thomas James Doyle sold 4,949 shares of Kura Oncology stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $38,948.
63. Following the completion of the sale, the senior vice president now owns 88,193 shares of the company’s stock, valued at $694,078.91.
This trade represents a 5.31 % decrease in their position. The disclosure for this sale can be found here.
Insiders sold a total of 11,729 shares of company stock valued at $92,307 over the last 90 days. 5.50% of the stock is owned by company insiders.
Kura Oncology Price PerformanceKURA stock opened at $5.77 on Friday. Kura Oncology, Inc.
has a 52-week low of $5.41 and a 52-week high of $23.48.
The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.
02. The stock has a market cap of $465.96 million, a price-to-earnings ratio of -2.
44 and a beta of 0.83. The business has a fifty day moving average of $7.
36 and a two-hundred day moving average of $10.86. Kura Oncology (NASDAQ:KURA – Get Free Report) last released its quarterly earnings results on Wednesday, February 26th.
The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.
43. The business had revenue of $53.88 million for the quarter, compared to analysts’ expectations of $57.
96 million. As a group, research analysts anticipate that Kura Oncology, Inc. will post -2.
44 earnings per share for the current year. Analyst Upgrades and DowngradesA number of brokerages have recently commented on KURA. HC Wainwright reiterated a “buy” rating and issued a $40.
00 target price on shares of Kura Oncology in a research report on Thursday, February 27th. Scotiabank cut their price objective on shares of Kura Oncology from $18.00 to $10.
00 and set a “sector perform” rating for the company in a report on Wednesday, January 8th. JMP Securities reissued a “market outperform” rating and issued a $28.00 target price on shares of Kura Oncology in a research note on Thursday, February 6th.
UBS Group dropped their price target on Kura Oncology from $27.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, March 6th.
Finally, Cantor Fitzgerald upgraded Kura Oncology to a “strong-buy” rating in a research report on Tuesday, March 4th. Three investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Kura Oncology presently has a consensus rating of “Moderate Buy” and an average price target of $25.
50.View Our Latest Research Report on Kura OncologyKura Oncology Profile (Free Report)Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer.
Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.Further ReadingFive stocks we like better than Kura OncologyWhat is the Dow Jones Industrial Average (DJIA)?Robinhood Strategies Could Be a Game-Changer for Young InvestorsWhat Are Some of the Best Large-Cap Stocks to Buy?Are These 3 Retail Stocks Oversold or Really in Trouble?What is Insider Trading? What You Can Learn from Insider TradingIONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are AheadWant to see what other hedge funds are holding KURA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kura Oncology, Inc.
(NASDAQ:KURA – Free Report)..
